NCT04428086View on ClinicalTrials.gov

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

August 22, 2021

Study Completion Date

August 22, 2021

Conditions
Solid Tumor, Adult
Interventions
DRUG

Apatinib in arm1

Apatinib will be administered at a dose of 250 mg once daily from Day 4 to Day 9.

DRUG

Rosuvastatin

Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.

DRUG

Apatinib in arm2

Apatinib will be administered at a dose of 250 mg once daily from Day 3 to Day 7.

DRUG

Metformin

Metformin will be administered as a single oral 500 mg on Day 1 and Day 6.

Trial Locations (1)

050035

The Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04428086 - A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. | Biotech Hunter | Biotech Hunter